Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Alanine Transaminase/*blood ; Aspartate Aminotransferases/*blood ; Carcinoma, Squamous Cell/*diagnosis ; Esophageal Neoplasms/*diagnosis ; gamma-Glutamyltransferase/*blood; Carcinoma, Squamous Cell/blood ; Carcinoma, Squamous Cell/enzymology ; Carcinoma, Squamous Cell/mortality ; Esophageal Neoplasms/blood ; Esophageal Neoplasms/enzymology ; Esophageal Neoplasms/mortality ; Esophageal Squamous Cell Carcinoma ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Retrospective Studies

Background: The levels of liver function tests (LFTs) are often used to assess liver injury and non-liver disease-related mortality. In our study, the relationship between pretreatment serum LFTs and overall survival (OS) was evaluated in esophageal squamous cell carcinoma (ESCC) patients.
Methods: Our purpose was to investigate the prognostic value of the preoperative alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in ESCC patients. A retrospective study was performed in 447 patients with ESCC, and follow-up period was at least 60 months until death. The prognostic significance of serum LFTs were determined by univariate and multivariate Cox hazard models.
Results: LFTs including ALT, AST, LSR, GGT, TBA and LDH were analyzed. Serum LSR (HR: 0.592, 95% CI = 0.457-0.768, p < 0.001 and GGT (HR: 1.507, 95% CI = 1.163-1.953, p = 0.002) levels were indicated as significant predictors of OS. The 5-year OS among patients with higher LSR levels was longer compared with those patients with decreased LSR levels, not only in the whole cohort but also in the subgroups stratified by pathological stage (T1-T2 subgroup, T3-T4 subgroup, N0 subgroup and M0 subgroup). We also found that patients with a higher GGT might predict worse OS than patients with a normal GGT, not only in the whole cohort but also in the subgroups stratified by pathological stage (T3-T4 subgroup and N1-N2 subgroup).
Conclusions: Both increased levels of LSR and decreased levels of GGT might predict shorter overall survival in ESCC patients. Our findings suggest that serum LSR and GGT levels could be used as a key predictor of survival in patients with ESCC.

Int J Mol Sci. 2016 Jun 09;17 (6):. (PMID: 27294917)
J Atheroscler Thromb. 2010 May;17(5):476-85. (PMID: 20228611)
J Epidemiol Community Health. 2007 Jul;61(7):591-6. (PMID: 17568050)
PLoS One. 2016 Feb 10;11(2):e0149122. (PMID: 26863311)
PLoS One. 2009;4(2):e4435. (PMID: 19209234)
Chest. 1999 Dec;116(6 Suppl):463S-465S. (PMID: 10619509)
BMJ. 2004 Apr 24;328(7446):983. (PMID: 15028636)
Ukr Biochem J. 2015 Sep-Oct;87(5):93-102. (PMID: 26717600)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Liver Int. 2014 Feb;34(2):171-3. (PMID: 24164713)
Free Radic Res. 2014 Jun;48(6):716-28. (PMID: 24684379)
Ann Thorac Surg. 2012 Feb;93(2):423-7. (PMID: 22178587)
Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355. (PMID: 11563810)
J Clin Oncol. 2007 Apr 1;25(10):1160-8. (PMID: 17401004)
Int J Hyg Environ Health. 2015 Jan;218(1):12-8. (PMID: 25455641)
N Engl J Med. 2003 Dec 4;349(23):2241-52. (PMID: 14657432)
Gastroenterology. 2002 Oct;123(4):1367-84. (PMID: 12360498)
Proc Soc Exp Biol Med. 1956 Apr;91(4):569-71. (PMID: 13323003)
World J Gastroenterol. 2006 Feb 28;12(8):1175-81. (PMID: 16534867)
Adv Exp Med Biol. 1980;132:647-54. (PMID: 6106999)
PLoS One. 2015 Oct 15;10(10):e0140323. (PMID: 26469700)
PLoS One. 2013;8(1):e49286. (PMID: 23326306)
BMC Cancer. 2016 Jul 21;16:516. (PMID: 27444612)
Medicine (Baltimore). 2016 Mar;95(12):e3158. (PMID: 27015199)
BMC Cancer. 2014 Jul 07;14 :490. (PMID: 25001061)
Tumour Biol. 2015 Nov;36(11):8903-11. (PMID: 26071675)
BMJ. 1995 Feb 18;310(6977):470. (PMID: 7873977)
Oncotarget. 2016 Jan 19;7(3):3111-27. (PMID: 26683522)
Int J Cancer. 2015 Mar 1;136(5):1162-70. (PMID: 25043373)
Diabetes Care. 2009 Apr;32(4):741-50. (PMID: 19131466)
Curr Pharm Des. 2012;18(26):3831-52. (PMID: 22632748)
Surgery. 2005 Feb;137(2):186-91. (PMID: 15674200)
Int J Cancer. 2016 Jan 15;138(2):311-9. (PMID: 26111622)
PLoS One. 2015 Apr 13;10(4):e0123246. (PMID: 25874561)
Nature. 2008 Jul 24;454(7203):436-44. (PMID: 18650914)
Ann Surg Oncol. 2014 Nov;21(12):3802-9. (PMID: 24849520)
Environ Health Perspect. 2006 Mar;114(3):350-4. (PMID: 16507456)
Eur J Epidemiol. 2013 Jul;28(7):541-50. (PMID: 23821244)
Carcinogenesis. 2015 Feb;36(2):243-8. (PMID: 25524924)

Keywords: Alanine aminotransferase/aspartate aminotransferase ratio; Esophageal squamous cell carcinoma; Gamma glutamyltransferase; Overall survival; Prognosis

EC 2.3.2.2 (gamma-Glutamyltransferase)
EC 2.6.1.1 (Aspartate Aminotransferases)
EC 2.6.1.2 (Alanine Transaminase)

Date Created: 20170816 Date Completed: 20180503 Latest Revision: 20220409

20231215

PMC5556356

10.1186/s12885-017-3523-y

28806937